Millennium Chief Medical Officer Nancy Simonian: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Exec discusses the firm's first year of profitability, the multiple myeloma market and current Velcade strategy following its copromotion deal with J&J.
You may also be interested in...
Millennium To Begin Phase III Trial For Velcade As First-Line Treatment For Multiple Myeloma
Velcade and Celgene’s Revlimid competing to be first with a first-line indication in MM.
Millennium To Begin Phase III Trial For Velcade As First-Line Treatment For Multiple Myeloma
Velcade and Celgene’s Revlimid competing to be first with a first-line indication in MM.
J&J’s Doxil Approved For Use With Velcade In Second-Line Multiple Myeloma
Combination will be detailed by J&J’s oncology sales force under copromotion agreement with Velcade maker Millennium.